scholarly article | Q13442814 |
P356 | DOI | 10.1111/J.1872-034X.2012.00982.X |
P8608 | Fatcat ID | release_q7dg2maxvjhlrlio5v2ddoi3fi |
P698 | PubMed publication ID | 22776551 |
P50 | author | Yusuke Kawamura | Q90407021 |
Hitomi Sezaki | Q92198438 | ||
Kenji Ikeda | Q114433562 | ||
Hiromitsu Kumada | Q114433568 | ||
Fumitaka Suzuki | Q114923480 | ||
Masahiro Kobayashi | Q114923755 | ||
Yoshiyuki Suzuki | Q114923935 | ||
Yasuji Arase | Q114924322 | ||
Satoshi Saito | Q114924602 | ||
Mariko Kobayashi | Q114924823 | ||
Tetsuya Hosaka | Q56223851 | ||
Norio Akuta | Q87747459 | ||
P2093 | author name string | Naoki Matsumoto | |
Yuya Seko | |||
Norihiro Imai | |||
P2860 | cites work | Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis | Q28183279 |
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C | Q29619541 | ||
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. | Q41604120 | ||
Interferon-beta plus ribavirin for patients with hepatitis C virus genotype 1: a randomised pilot trial | Q42844274 | ||
Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy | Q42981569 | ||
Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load | Q42982755 | ||
Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment. | Q42987233 | ||
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study | Q42989003 | ||
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. | Q42993387 | ||
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load | Q42997474 | ||
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. | Q42998703 | ||
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients. | Q43040948 | ||
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. | Q44527614 | ||
Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C. | Q50568065 | ||
Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C. | Q50569792 | ||
Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. | Q50577281 | ||
A high-throughput SNP typing system for genome-wide association studies | Q57269468 | ||
P433 | issue | 8 | |
P921 | main subject | ribavirin | Q421862 |
chronic hepatitis C | Q55779873 | ||
P304 | page(s) | 750-756 | |
P577 | publication date | 2012-03-26 | |
P1433 | published in | Hepatology Research | Q15752035 |
P1476 | title | Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load | |
P478 | volume | 42 |
Q41750179 | Efficacy and safety of interferon treatment in elderly patients with chronic hepatitis C in Japan: A retrospective study using the Japanese Interferon Database. |
Q47888797 | Efficacy and safety of telaprevir with natural human interferon-β and ribavirin in Japanese chronic hepatitis C patients with depression |
Q42090330 | Evolution of viral RNA in a Chinese patient to interferon/ribavirin therapy for hepatitis C. |
Q35668734 | Natural interferon-beta treatment for patients with chronic hepatitis C in Japan |
Search more.